Full Press Release Details
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
2024 Wells Fargo Healthcare Conference
Management will participate in one-on-one meetings on Wednesday, September 4
Morgan Stanley 22nd Annual Global Healthcare Conference
Presentation: Friday, September 6, 2024, at 8:30 a.m. EDT at the Marriott Marquis, New York, New York
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings on Friday, September 6
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)